Login to Your Account

Affiris Gets $34M for Vaccines Now and $41M Option Later

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 16, 2011
Affiris AG raised €25 million (US$34 million) in new equity funding and could land another €30 million from the same investors, to take forward its pipeline of clinical and preclinical peptide-based therapeutic vaccine candidates, which are in development for a range of neurodegenerative, cardiovascular and metabolic disorders.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription